In summary, we have demonstrated in the present study that scFv‐IL‐13Rα2‐CAR‐T cells can efficiently target IL‐13Rα2 overexpressing human tumour cells in vitro and in pre‐clinical models of human glioma cancers as the binding of our newer clone #14‐1 in scFv‐IL‐13Rα2‐ CAR construct is ∼5 times more than the previous clone #4.30, 65. The gene discussed is IL13RA2; the disease is central nervous system cancer.